Seminar: SFO Epidemiology Awardees
Three New SFO Awardees will present their projects.
Lisen Arnheim Dahlström
Title: Comprehensive population-based evaluation of the benefits and risks of HPV vaccination
Abstract: The Human papilloma virus (HPV) vaccine has been available since 2006. In Sweden the vaccine was subsidized for girls age 13-17 until 2012 when HPV-vaccination became part of the school-vaccination program. In addition to protection against cervical cancer, one of the two existing HPV vaccines also offers protection against genital warts. We have successfully studied the effectiveness of the HPV vaccine against genital warts in the Swedish population during the five first years after its introduction. However, genital warts are not caused by the same HPV types as those causing cervical cancer. Therefore, there is a need to also investigate vaccine effectiveness on other HPV related outcomes such as precancerous lesions of the cervix. Further, the continuous evaluation on vaccine safety is important to ensure an acceptable balance between benefits and risks with HPV vaccines and to maintain public trust in the vaccine program.
Title: Prevention of upper-gastrointestinal cancer
Abstract: Upper-gastrointestinal cancer accounts globally for almost 20% of all new cancers and 25% of cancer deaths. The survival of these types of cancer has not improved much despite of decades of attempts to improve the treatment. Therefore the aim of this project is to explore strategies to prevent these types of cancer, such as chemoprevention (by commonly prescribed drugs such as anti-reflux medication, hormone replacement therapy and Helicobacter pylori eradication), and treatment of gastro-oesophageal reflux and obesity. These studies are based on 2 population-based Nordic cohorts and a Swedish population-based study based on the Swedish Drug Registry.
Title: Alteration in energy metabolism – a prodromal symptom of amyotrophic lateral sclerosis?
Abstract: Besides motor neuron degeneration, ALS patients are known to have several defects in energy metabolism, including weight loss, hypermetabolism, and dyslipidemia, which are also associated with ALS progression. Although experimental data have shown that such features initiate early in life, no human studies have yet addressed the temporal relation of energy metabolism and ALS. Our preliminary findings suggest that altered energy metabolism is also present among pre-symptomatic ALS patients. Potential underlying mechanisms for the early demonstration of energy metabolism alteration in ALS will be discussed.
Lunch sandwiches will be provided. R.S.V:P to email@example.com by December 10.Contact person: Maria Berner Holmström